Even though we have demonstrated a higher risk of NAION in persons with T2D exposed to once-weekly semaglutide, it is important to keep in mind that use of semaglutide comes with substantial advantages for patients as given by the improved glycemic control, reduction in risk of cardiovascular disease as well as the beneficial effects of weight loss [1]
No increased risk of pancreatitis, diabetic retinopathy complications, or major cardiovascular events was observed, though longer-term safety data continues to accumulate
Cardiovascular and Kidney Outcomes No dedicated prospective RCT has yet been powered to compare combined SGLT2i and GLP-1RA therapy versus monotherapy for cardiovascular and kidney endpoints, although the ongoing PRECIDENTD trial is expected to address this gap [36]
Wang CL, Hsu KH, Chang YH, Ho CC, Chiang CJ, Chen KC, Cheung YC, Huang PC, Chen YR, Chen CY, et al
Neither provides enough progressive resistance to counteract GLP-1 muscle loss